Entry |
|
Name |
Omeprazole magnesium, amoxicillin and rifabutin; Talicia (TN) |
Product |
|
Component |
|
Class |
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
DG01633 CYP3A/CYP3A4 substrate
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
|
Remark |
|
Efficacy |
Antibacterial |
Disease |
Helicobacter pylori infection [DS: H00320] |
Comment |
Rifabutin is a substrate and an inducer of CYP3A.
Omeprazole is a substrate and an inhibitor of CYP2C19, and a substrate of CYP3A4.
|
Metabolism |
|
Interaction |
CYP induction: CYP3A [HSA: 1576 1577 1551]
CYP inhibition: CYP2C19 [HSA: 1557]
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A02 DRUGS FOR ACID RELATED DISORDERS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02BD Combinations for eradication of Helicobacter pylori
A02BD16 Omeprazole, amoxicillin and rifabutin
D11858 Omeprazole magnesium, amoxicillin and rifabutin <US>
USP drug classification [BR:br08302]
Gastrointestinal Agents
Gastrointestinal Agents, Other
Amoxicillin/ Omeprazole Magnesium/ Rifabutin
D11858 Omeprazole magnesium, amoxicillin and rifabutin
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01639 CYP2C19 substrate
D11858 Omeprazole magnesium, amoxicillin and rifabutin
DG01633 CYP3A/CYP3A4 substrate
D11858 Omeprazole magnesium, amoxicillin and rifabutin
Metabolizing enzyme inhibitor
DG01933 CYP2C19 inhibitor
D11858 Omeprazole magnesium, amoxicillin and rifabutin
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
D11858 Omeprazole magnesium, amoxicillin and rifabutin
Antimicrobials [BR:br08307]
Antibacterials
Cell wall biosynthesis inhibitor, beta-lactam
Combination for eradication of H. pylori
D11858 Omeprazole magnesium, amoxicillin and rifabutin <US>
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11858
|
Other DBs |
|
LinkDB |
|